Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma

Annals of Surgical Oncology

Volumn 15, Issue 2, 2008, Pages 583-589

  Uenishi, Takahiro ^a   Yamazaki, Osamu ^b   Tanaka, Hiromu ^a   Takemura, Shigekazu ^a   Yamamoto, Takatsugu ^a   Tanaka, Shogo ^a   Nishiguchi, Shuhei ^c   Kubo, Shoji ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA CITY GENERAL HOSPITAL   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Cytokeratin 19 fragment; Intrahepatic cholangiocarcinoma; Liver resection; Postoperative outcome; Tumor marker

Indexed keywords

CARBOHYDRATE ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; ANTIGEN CYFRA21.1; CA 19-9 ANTIGEN; KERATIN; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BILE DUCT CARCINOMA; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; HUMAN; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; PROGNOSIS; ROC CURVE; SENSITIVITY AND SPECIFICITY; UNIVARIATE ANALYSIS; YOUDEN INDEX; BILE DUCT TUMOR; BLOOD; CANCER INVASION; DISEASE FREE SURVIVAL; INTRAHEPATIC BILE DUCT; LYMPH NODE METASTASIS; MORTALITY; PATHOLOGY;

AGED; ANTIGENS, NEOPLASM; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHOLANGIOCARCINOMA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KERATINS; LYMPHATIC METASTASIS; MALE; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; PROGNOSIS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 40649084361     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-007-9650-y     Document Type: Article

References (50)

1. Kobayashi M, Ikeda K, Saitoh S, et al. Incidence of primary cholangiocellular carcinoma of the liver in Japanese patients with hepatitis C virus-related cirrhosis. Cancer 2000; 88:2471-7
2. Shaib YH, El-Serag HB, Davila JA, et al. Risk factors of intrahepatic cholangiocarcinoma in the United States: A case-control study. Gastroenterology 2005; 128:620-6
3. Kawarada Y, Mizumoto R. Cholangiocellular carcinoma of the liver. Am J Surg 1984; 147:354-9
4. Kawarada Y, Mizumoto R. Diagnosis and treatment of cholangiocellular carcinoma of the liver. Hepatogastroenterology 1990; 37:176-81
5. Yamanaka N, Okamoto E, Ando T, et al. Clinicopathologic spectrum of resected extraductal mass-forming intrahepatic cholangiocarcinoma. Cancer 1995; 76:2449-56
6. Chu KM, Lai EC, Al-Hadeedi S, et al. Intrahepatic cholangiocarcinoma. World J Surg 1997; 21:301-6
7. Kim HJ, YunN SS, Jung KH, et al. Intrahepatic cholangiocarcinoma in Korea. J Hep Bil Pancr Surg 1999; 6:142-8
8. Uenishi T, Hirohashi K, Kubo S, et al. Clinicopathologic factors predicting outcome after resection of mass-forming intrahepatic cholangiocarcinoma. Br J Surg 2001; 88:969-74
9. Pujol JL, Grenier J, Daures JP, et al. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res 1993; 53:61-6
10. Sugama Y, Kitamura S, Kawai T, et al. Clinical usefulness of CYFRA assay in diagnosing lung cancer: measurement of serum cytokeratin fragment. Jpn J Cancer Res 1994; 85:1178-84
11. Takada M, Masuda N, Matsuura E, et al. Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay. Br J Cancer 1995; 71:160-5
12. Brechot JM, Chevret S, Nataf J, et al. Diagnostic and prognostic value of Cyfra 21-1 compared with other tumour markers in patients with non-small cell lung cancer: a prospective study of 116 patients. Eur J Cancer 1997; 33:385-91
13. Nisman B, Lafair J, Heching N, et al. Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information? Cancer 1998; 82:1850-9
14. Uenishi T, Kubo S, Hirohashi K, et al. Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer. Br J Cancer 2003; 88:1894-9
15. Inoue K, Makuuchi M, Takayama T, et al. Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma. Surgery 2000; 127:498-505
16. Shirabe K, Shimada M, Harimoto N, et al. Intrahepatic cholangiocarcinoma: Its mode of spreading and therapeutic modalities. Surgery 2002; 131(1 Suppl):S159-64
17. Moro D, Villemain D, Vuillez JP, et al. CEA, CYFRA21-1 and SCC in non-small cell lung cancer. Lung Cancer 1995; 13:169-76
18. Takei Y, Minato K, Tsuchiya S, et al. CYFRA 21-1: an indicator of survival and therapeutic effect in lung cancer. Oncology 1997; 54:43-7
19. Pujol JL, Molinier O, Ebert W, et al. CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer 2004; 90:2097-105
20. Mizuguchi S, Nishiyama N, Iwata T, et al. Clinical value of serum cytokeratin 19 fragment and sialyl-Lewis x in non-small cell lung cancer. Ann Thorac Surg 2007; 83:216-21
21. Doweck I, Barak M, Uri N, et al. The prognostic value of the tumour marker Cyfra 21-1 in carcinoma of head and neck and its role in early detection of recurrent disease. Br J Cancer 2000; 83:1696-701
22. Brockmann JG, St Nottberg H, Glodny B, et al. CYFRA 21-1 serum analysis in patients with esophageal cancer. Clin Cancer Res 2000; 6:4249-52
23. Shimada H, Nabeya Y, Okazumi S, et al. Prognostic significance of CYFRA 21-1 in patients with esophageal squamous cell carcinoma. J Am Coll Surg 2003; 196:573-8
24. Nakata B, Takashima T, Ogawa Y, et al. Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer. Br J Cancer 2004; 91:873-8
25. Nakata B, Chung YS, Kato Y, et al. Clinical significance of serum CYFRA 21-1 in gastric cancer. Br J Cancer 1996; 73:1529-32
26. Sobin LH, Wittekind CH. TNM classification of malignant tumors, Fifth edition. New York: Wiley-Liss, 1997
27. Metz CE, Herman BA, Roe CA. Statistical comparison of two ROC-curve estimates obtained from partially-paired datasets. Med Decis Making 1998; 18:110-21
28. Youden WJ. Index for rating diagnostic tests. Cancer 1950; 3:32-5
29. Loyer EM, Chin H, DuBrow RA, et al. Hepatocellular carcinoma and intrahepatic peripheral cholangiocarcinoma: enhancement patterns with quadruple phase helical CT-a comparative study. Radiology 1999; 212:866-75
30. Iwata Y, Shiomi S, Sasaki N, et al. Clinical usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in the diagnosis of liver tumors. Ann Nucl Med 2000; 14:121-6
31. Jadvar H, Henderson RW, Conti PS. [F-18] fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma. J Comput Assist Tomogr 2007; 31:223-8
32. Harrison LE, Fong Y, Klimstra DS, et al. Surgical treatment of 32 patients with peripheral intrahepatic cholangiocarcinoma. Br J Surg 1998; 85:1068-70
33. Sorensen HT, Friis S, Olsen JH, et al. Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology 1998; 28:921-5
34. Yamamoto S, Kubo S, Hai S, et al. Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma. Cancer Sci 2004; 95:592-5
35. Ohtsuka M, Ito H, Kimura F, et al. Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival. Br J Surg 2002; 89:1525-31
36. Madariaga JR, Iwatsuki S, Todo S, et al. Liver resection for hilar and peripheral cholangiocarcinoma: A study of 62 cases. Ann Surg 1998; 227:70-9
37. Casavilla FA, Marsh JW, Iwatsuki S, et al. Hepatic resection and transplantation for peripheral cholangiocarcinoma. J Am Coll Surg 1997; 185:429-36
38. Kawarada Y, Yamagiwa K, Das BC. Analysis of the relationships between clinicopathologic factors and survival time in intrahepatic cholangiocarcinoma. Am J Surg 2002; 183:679-85
39. Shimada M, Yamashita Y, Aishima S, et al. Value of lymph node dissection during resection of intrahepatic cholangiocarcinoma. Br J Surg 2001; 88:1463-6
40. Nakagawa T, Kamiyama T, Kurauchi N, et al. Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma. World J Surg 2005; 29:728-33
41. Uenishi T, Yamazaki O, Horii K, et al. A long-term survivor of intrahepatic cholangiocarcinoma with paraaortic lymph node metastasis. J Gastroenterol 2006; 41:391-2
42. Murakami Y, Yokoyama T, Takesue Y, et al. (2000) Long-term survival of peripheral intrahepatic cholangiocarcinoma with metastases to the para-aortic lymph nodes. Surgery 2000; 127:105-6
43. Stathopoulos EN, Sanidas E, Kafousi M, et al. Detection of CK-19 mRNA-positive cells in the peripheral blood of breast cancer patients with histologically and immunohistochemically negative axillary lymph nodes. Ann Oncol 2005; 16:240-6
44. Chen TF, Jiang GL, Fu XL, et al. CK19 mRNA expression measured by reverse-transcription polymerase chain reaction (RT-PCR) in the peripheral blood of patients with non-small cell lung cancer treated by chemo-radiation: an independent prognostic factor. Lung Cancer 2007; 56:105-14
45. Andre T, Tournigand C, Rosmorduc O, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 2004; 15:1339-43
46. Cho JY, Paik YH, Chang YS, et al. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. Cancer 2005; 104:2753-8
47. Kim ST, Park JO, Lee J, et al. A phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer 2006; 106:1339-46
48. Hsu C, Shen YC, Yang CH, et al. Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract. Br J Cancer 2004; 90:1715-9
49. Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007; 96:896-902
50. Nakeeb A, Tran KQ, Black MJ, et al. Improved survival in resected biliary malignancies. Surgery 2002; 132:555-64